4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

ReturnOfEsquire Mar. 11 at 2:51 PM

$FDMT https://www.perplexity.ai/search/4front-1-and-4front-2-trial-de-gCI3sg1NQa606Hne5qC_Wg

0 · Reply

Quantumup Mar. 9 at 1:14 PM

Mizuho $EYPT OP$36 $OCUL $REGN RHHBY KOD $SRZN $FDMT Mizuho said—EYPT reported 4Q results last week, with progress continuing for lead asset Duravyu, with (1) top-line P3 study data in wet AMD/wAMD still expected beginning in mid-2026, and (2) first patient dosing achieved in both P3 studies in diabetic macular edema/DME (with readouts expected in 2H27) That said, given recent reporting of first P3 data for competitor Ocular Therapeutix' (OCUL, NC) Axpaxli, investor debates remain highly active regarding potential differentiation between the two assets, and not surprisingly, this was the main focus on EYPT's 4Q call With this in mind, seeing (1) differentiated/improved efficacy and safety, (2) a better P3 trial design, and (3) a more straightforward path to approval and commercial uptake, we continue to believe Duravyu is better-positioned to become the best-in-class TKI-based maintenance therapy for wAMD As such, we stay Outperform-rated on EYPT, and view recent weakness as a buying opportunity

0 · Reply

Quantumup Mar. 4 at 8:05 PM

Chardan⬆️the PT on $EYPT to $29 from $27 and reiterated at a Buy rating. $OCUL $REGN RHHBY $SRZN KOD $FDMT Chardan said in its note—EyePoint reported 4Q25 financial results and provided updates on its Duravyu programs. The company ended the quarter with cash, cash equivalents, and marketable securities of $306 mm, with the projected operational runway into 4Q27. Updating our forward estimates raises our PT to $29 from $27. The next big catalyst for EyePoint is the Phase 3 Duravyu data from LUGANO and LUCIA trials in mid-2026. Our confidence in this program remains high, supported by robust Phase 2 data and the recently reported SOL-1 data from Ocular Therapeutics (Buy), which, we believe, provides further validation of the TKI MoA in wet AMD.

0 · Reply

ReturnOfEsquire Mar. 4 at 6:41 PM

$FDMT LOL...up almost 10% from this POS post.

0 · Reply

BillionerOfKing Mar. 3 at 11:40 PM

$FDMT Current Stock Price: $8.45 Contracts to trade: $8.0 FDMT Mar 20 2026 Call Entry: $2.07 Exit: $3.12 ROI: 51% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Mar. 3 at 7:12 PM

$FDMT RSI: 41.56, MACD: 0.1725 Vol: 0.41, MA20: 9.30, MA50: 8.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

xxxxxxx01 Feb. 27 at 7:09 PM

$FDMT coming back here with a hefty balance made else where 🔥🔥

0 · Reply

senile_nurse Feb. 26 at 5:35 AM

$FDMT Somebody asked about the earnings date — according to zacks.com and other earnings calendars, the next expected earnings report is Feb 27, 2026 (may vary slightly when finally announced).

0 · Reply

RaKa82 Feb. 24 at 11:38 PM

$FDMT Has anyone seen senile_nurse lately? Asking for a friend 😂😂

0 · Reply

ppl_first Feb. 24 at 6:50 PM

$FDMT Gene therapy binary. Long timeline with volatility between updates. If your goal is asymmetric upside through 2026, FDMT is appropriate to hold. If you want near-term movement, it will frustrate you.

0 · Reply

4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 6, 2026, 1:46 PM EST - 9 days ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Feb 19, 2026, 8:00 AM EST - 24 days ago

4DMT to Participate in Upcoming Investor Conferences

Feb 13, 2026, 4:05 PM EST - 4 weeks ago

4DMT Announces New Employment Inducement Grants

Feb 9, 2026, 8:00 AM EST - 4 weeks ago

4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD

Jan 14, 2026, 1:35 PM EST - 2 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 7, 2026, 8:00 AM EST - 2 months ago

4DMT Provides Company Update and Anticipated Development Milestones for 2026

Dec 17, 2025, 12:59 PM EST - 3 months ago

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

Dec 17, 2025, 7:00 AM EST - 3 months ago

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

Dec 8, 2025, 8:00 AM EST - 3 months ago

4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 21, 2025, 7:43 PM EST - 4 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 8:00 AM EST - 4 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 6:00 AM EST - 4 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 10, 2025, 8:00 AM EST - 4 months ago

4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 6, 2025, 4:05 PM EST - 4 months ago

4DMT to Participate in Jefferies 2025 London Healthcare Conference

Nov 6, 2025, 6:23 AM EST - 4 months ago

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Nov 6, 2025, 6:00 AM EST - 4 months ago

4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Oct 30, 2025, 11:02 PM EDT - 4 months ago

4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific

Oct 14, 2025, 8:00 AM EDT - 5 months ago

4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 13, 2025, 8:00 AM EDT - 5 months ago

4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation

Sep 30, 2025, 5:08 AM EDT - 5 months ago

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 9, 2025, 6:13 PM EDT - 6 months ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 6 months ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 11, 2025, 8:00 AM EDT - 7 months ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 7 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 8 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 8 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 8 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 9 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 11 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 11 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 1 year ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 1 year ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 1 year ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 1 year ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 1 year ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 1 year ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

ReturnOfEsquire Mar. 11 at 2:51 PM

$FDMT https://www.perplexity.ai/search/4front-1-and-4front-2-trial-de-gCI3sg1NQa606Hne5qC_Wg

0 · Reply

Quantumup Mar. 9 at 1:14 PM

0 · Reply

Quantumup Mar. 4 at 8:05 PM

0 · Reply

ReturnOfEsquire Mar. 4 at 6:41 PM

$FDMT LOL...up almost 10% from this POS post.

0 · Reply

BillionerOfKing Mar. 3 at 11:40 PM

0 · Reply

OfficialStocktwitsUser Mar. 3 at 7:12 PM

0 · Reply

xxxxxxx01 Feb. 27 at 7:09 PM

$FDMT coming back here with a hefty balance made else where 🔥🔥

0 · Reply

senile_nurse Feb. 26 at 5:35 AM

$FDMT Somebody asked about the earnings date — according to zacks.com and other earnings calendars, the next expected earnings report is Feb 27, 2026 (may vary slightly when finally announced).

0 · Reply

RaKa82 Feb. 24 at 11:38 PM

$FDMT Has anyone seen senile_nurse lately? Asking for a friend 😂😂

0 · Reply

ppl_first Feb. 24 at 6:50 PM

0 · Reply

Elledoeshair Feb. 24 at 4:38 PM

$FDMT added

0 · Reply

McMillion1 Feb. 24 at 12:09 PM

$IOVA $6 $VIR $FDMT $CUE $FBLG

0 · Reply

MOTP Feb. 24 at 2:16 AM

$FDMT wondering when are the earnings for this one? What are the expectations?

0 · Reply

eeyore1 Feb. 23 at 4:51 AM

$FDMT 20.42% short float — that’s serious fuel. It won’t take much upside momentum to start forcing covers. If this catches a bid, the squeeze could be sharp and fast.

0 · Reply

vulture2 Feb. 23 at 4:48 AM

$FDMT The real catalyst clock is ticking toward H1 2027 with 4FRONT-1 Phase 3 topline for 4D-150. That’s the kind of event that can completely re-rate a biotech. Between now and then, every update tightens the setup. Patience into a registrational readout — that’s where the asymmetric upside lives.

0 · Reply

xxxxxxx01 Feb. 20 at 6:57 PM

$FDMT $IBRX 2 biotechs that will carry my portfolio for the next 2 years 🔥🔥🔥🔥unbelievable companies

0 · Reply

ReturnOfEsquire Feb. 19 at 4:12 PM

$FDMT Let's go baby...

0 · Reply

Larrymme Feb. 19 at 2:57 PM

$FDMT

0 · Reply

vulture2 Feb. 19 at 3:26 AM

$FDMT 4.3 “rescue shots over 24 months” isn’t “about the same as Eylea” — that’s supplemental anti-VEGF after a one-time 4D-150 dose (and it’s from the toughest PRISM cohort). PRISM breaks it out by 6-month chunks (~0.5 / 1.3 / 1.2 / 1.2 = ~4.2 total through 24 mo). The Phase 3 comparator is projected aflibercept q8w (i.e., way more injections). Apples vs oranges.

1 · Reply

Aawilliam2003 Feb. 18 at 5:16 PM

$FDMT can someone help with the hype here. Doesn’t their data show 4.3 rescue shots over 24 months? Isn’t that about the same as Elena?

2 · Reply

xxxxxxx01 Feb. 17 at 8:30 PM

$OCUL very happy with my position on this . This will be best in class until $FDMT takes over I Will hold until buyout or until they file a NDA

0 · Reply

ReturnOfEsquire Feb. 17 at 4:38 PM

$FDMT This is where OCUL failed. Durability is far worse than our 92% injection free in treatment naive.

1 · Reply

Market Cap	475.93M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	466,200
Avg Vol	758,870
Day's Range	N/A - N/A
Shares Out	57.14M
Stochastic %K	28%
Beta	2.99
Analysts	Strong Sell
Price Target	$33.11